15 % Azelainsäuregel in der Behandlung der Akne. Zwei doppelblinde klinische Vergleichsstudien

  title={15 \% Azelains{\"a}uregel in der Behandlung der Akne. Zwei doppelblinde klinische Vergleichsstudien},
  author={Harald P. M. Gollnick and K. Graupe and R.‐P. Zaumseil},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
Hintergrund: Die topische Behandlung ist die Therapie erster Wahl für die milde bis mittelschwer ausgeprägte Acne vulgaris. Azelainsäure ist als 20%ige Cremeformulierung seit 15 Jahren als ein wirksames und sicheres Externum etabliert. Eine neue, nicht‐alkoholische Hydrogelformulierung mit 15 % Azelainsäure wurde klinisch gegenüber den Standardexterna 5 % Benzoylperoxid (BPO) und 1 % Clindamycin getestet. 

Azelainsäure 15 % Gel in der Behandlung der Acne vulgaris

In der Therapie der leichten bis mittelschweren Acne vulgaris ist der Einsatz topischer Aknetherapeutika Mittel der ersten Wahl. Bevorzugt werden solche Substanzen, die mehr als einen Faktor in der

Medikamentöse Therapie der Akne

Acne is treated according to the clinical picture and the pathophysiologically relevant mechanisms, such as seborrhea, follicular hyperkeratosis, P. acnes colonisation,and inflammation.

Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris

The combination of AA 5% and erythromycin 2% produced more potent therapeutic effects in comparison with erythaic acid 5% or AA 20% alone, and with fewer side effects.

Topical acne treatments in Europe and the issue of antimicrobial resistance

An update on the current topical acne treatments available in Europe, their mechanism of action, their potential to induce antimicrobial resistance and their clinical efficacy and safety are provided.

Therapy of acne: azelaic acid and basic care

The authors describe mechanisms of the effect of azelaic acid on major stages of the pathogenesis of acne and substantiate the need in basic care in the treatment of acne by the example of products of the JOYSKIN line.

Overview of new therapeutic developments for acne

Recent studies have demonstrated the clinical efficacy of topical retinoids in maintenance therapy of acne, which supports the currently refined understanding of acne as a chronic disease.

A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris

Mild‐to‐moderate acne vulgaris is treated with a range of mono‐ and combination therapies; however, clinical evidence is still required to optimize treatment recommendations.

A randomized investigator‐blind parallel‐group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne

Growing numbers of post‐adolescent females are suffering from treatment‐resistant or relapsing adult acne forms, therefore requiring the definition of safe and effective treatment options for this

Experience use of azelaic acid in patients with acne

The results of the study indicate a high level of safety and tolerability of the Azelik-gel and obtained clinical results have shown its therapeutic efficacy in the treatment of papulo-pustular acne mild to moderate in severity.

Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vulgaris 2017

The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017, which more strongly recommend combination therapies, especially fixed‐dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase.



The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy

AZA induced a reduction in follicular hyperkeratosis of a similar magnitude to that induced by RA, and there was a significant reduction in the AZA and RA groups.

Topical Acne Drugs

Animal data support avoidance of many topical agents, particularly known teratogens such as retinoids and salicylic acid, in pregnant women, and recommend caution in special circumstances, such as during childhood, pregnancy, lactation and concomitant therapy with other drugs, because relevant studies are lacking.

Management of acne: a report from a Global Alliance to Improve Outcomes in Acne.

The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria

The combined formulation was significantly more effective at reducing total propionibacterial numbers at 6 and 12 weeks than erythromycin alone, although, after 12 weeks, the anti‐propionib bacterial efficacy of both preparations was less marked.

Topical Treatment in Acne: Current Status and Future Aspects

Topical antimicrobials, in particular topical antibiotics, should be used less often than in the past and only for short periods to avoid the development of resistances and the physical removal by electrocautery or CO2 laser of multiple densely packed closed comedones, macrocomedones and microcysts is necessary to enhance the efficacy of topical comedolytic agents and to speed up the therapeutic results.

Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases

The reported clinical effectiveness of azelaic acid is partly due to its inhibitory action on neutrophil-generated ROS, leading to a reduction both in oxidative tissue injury at sites of inflammation and in melanin formation.

Antibiotic resistant propionibacteria in acne: need for policies to modify antibiotic usage.

There was still a similar delay in recognising the condition before admission since there were no significant differences between the two periods with regard to age on admission, duration of vomiting, and state of hydration on presentation.

Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro.

Findings show that AZA exerts a dose- and time-dependent, reversible antiproliferative effect on keratinocytes, acting primarily on mitochondria and RER, which could explain its beneficial effect in some skin disorders characterized by alteration of keratinocytic differentiation.